Table 6. Demographic characteristics, prior seasonal influenza vaccine, and study site, by study group.

	Post 1st dose administration				Post 2nd dose administration
STUDY GROUP	AEs	Participants	AE per participant		AEs	Participants	AE per participant
	n o	with AE (n o )	Median	(P 25 -P 75 )	n o	with AE (n o )	Median	(P 25 -P 75 )
Group 1A: 15μg H7N9 + IB160	135	47	2	(1–4)	83	39	2	(1–3)
Group 1B: 7.5μg H7N9 + IB160	134	43	2	(1–4)	105	39	2	(2–4)
Group 1C: 3.75μg H7N9 + IB160	111	46	2	(1–3)	113	37	3	(1–4)
Group 2A: 15μg H7N9 + SE	94	37	2	(1–4)	58	28	2	(1–3)
Group 2B: 7.5μg H7N9 + SE	108	46	2	(1–3)	91	33	2	(1–3)
Group 2C: 3.75μg H7N9 + SE	95	37	2	(1–3)	91	36	2	(1–3)
Group 3: 15μg H7N9 without adjuvant	86	33	2	(1–4)	59	26	2	(1–3)
Group 4: Placebo	88	37	2	(1–3)	39	21	2	(1–2)
TOTAL	851	326	2	(1–3)	639	259	2	(1–3)
STUDY GROUP	ARs	Participants	AR per participant		ARs	Participants	AR per participant
	n o	with AR (n o )	Median	(P 25 -P 75 )	n o	with AR (n o )	Median	(P 25 -P 75 )
Group 1A: 15μg H7N9 + IB160	120	47	2	(1–3)	71	38	1	(1–2)
Group 1B: 7.5μg H7N9 + IB160	122	41	2	(1–4)	86	37	2	(1–3)
Group 1C: 3.75μg H7N9 + IB160	95	45	2	(1–3)	95	36	2	(1–3.5)
Group 2A: 15μg H7N9 + SE	82	35	2	(1–3)	49	25	2	(1–3)
Group 2B: 7.5μg H7N9 + SE	94	43	1	(1–2)	76	28	2	(1–3)
Group 2C: 3.75μg H7N9 + SE	81	33	2	(1–3)	70	32	1.5	(1–2.5)
Group 3: 15μg H7N9 without adjuvant	72	31	2	(1–3)	43	23	2	(1–2)
Group 4: Placebo	68	33	2	(1–3)	30	15	2	(1–3)
TOTAL	734	308	2	(1–3)	520	234	2	(1–3)

adj: adjuvant; P₂₅: first quartile; P₇₅: third quartile